Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.

ABSTRACT:

Background

To observe the influence of combination treatment with glibenclamide and CoCl(2) on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9.

Methods

50 adult female TA2 mice were randomly divided into 5 groups including DMSO control, CoCl(2), glibenclamide, CoCl(2) + glibenclamide and paclitaxel. All of these mice were inoculated with TA2 spontaneous breast cancer cells in the left groin. Nine days after inoculation the tumor could be palpated. Different treatments for each group were then subcutaneously administered near the tumors on the 9th and 14th days after injection. Tumor size was measured to determine the growth curve. All mice were sacrificed on the 18th day after initial inoculation and tumor tissues were

SUBMITTER: Rong Z 

PROVIDER: S-EPMC3680297 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature